0053| Volume 128, SUPPLEMENT , 155012, March 2022

Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Severe Hypertriglyceridemia (SHTG) – Initial Baseline data from an Ongoing Phase 2 Study

      Background/Synopsis: Fibroblast growth factor 21 (FGF21) is an endogenous metabolic hormone that regulates energy expenditure, lipid, and carbohydrate metabolism. BIO89-100, a glycoPEGylated FGF21 analog, is currently being evaluated in ENTRIGUE, a “Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety in Subjects with Severe Hypertriglyceridemia.”
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect